
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 11, 2015

OCULAR THERAPEUTIX, INC.
(Exact Name of Company as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-36554
(Commission
File Number)

20-5560161
(IRS Employer
Identification No.)

**34 Crosby Drive, Suite 105
Bedford, MA 01730**
(Address of Principal Executive Offices) (Zip Code)

Company's telephone number, including area code: (781) 357-4000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.07 Submission of Matters to a Vote of Security Holders.

Ocular Therapeutix held its Annual Meeting of Stockholders on June 11, 2015. The following is a summary of the matters voted on at that meeting.

- (a) Ocular Therapeutix’s stockholders elected James Garvey and Charles Warden as Class I directors to serve until the 2018 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows:

Name	<u>Votes For</u>	<u>Votes Withheld</u>	<u>Broker Non-Votes</u>
James Garvey	16,954,097	899,977	1,381,753
Charles Warden	17,373,126	480,948	1,381,753

- (b) Ocular Therapeutix’s stockholders ratified the selection of PricewaterhouseCoopers LLP as Ocular Therapeutix’s independent registered public accounting firm for the current fiscal year. The result of the stockholders’ vote with respect to such ratification were as follows:

For	Against	Abstain	Broker Non-Votes
19,221,325	14,502	0	0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OCULAR THERAPEUTIX, INC.

Date: June 11, 2015

By: /s/ W. Bradford Smith

W. Bradford Smith

Chief Financial Officer